PPAR-COMBO With Sulfonylurea

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00162175
First received: September 9, 2005
Last updated: September 10, 2010
Last verified: September 2007
  Purpose

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.


Condition Intervention Phase
Metabolics Diabetes Nos
Drug: Muraglitazar
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + glyburide vs placebo + glyburide

Secondary Outcome Measures:
  • Change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24

Estimated Enrollment: 534
Study Start Date: July 2003
Study Completion Date: November 2005
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 Diabetes, HbA1c > 7.0% and < 10.0%, mean serum triglyceride < 600 mg/dL, body mass index < 41 kg/m2, fasting c-peptide . 1.5 ng/mL.

Exclusion Criteria:

  • History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months, congestive heart failure (NYHA Class III and IV, uncontrolled hypertension, history or renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00162175

  Hide Study Locations
Locations
United States, Alabama
Local Institution
Anniston, Alabama, United States
Local Institution
Hoover, Alabama, United States
Local Institution
Huntsville, Alabama, United States
Local Institution
Mobile, Alabama, United States
United States, Arizona
Local Institution
Mesa, Arizona, United States
Local Institution
Phoenix, Arizona, United States
Local Institution
Tucson, Arizona, United States
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
Encinitas, California, United States
Local Institution
Long Beach, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
Mission Viejo, California, United States
Local Institution
Pasadena, California, United States
Local Institution
San Diego, California, United States
Local Institution
Walnut Creek, California, United States
Local Institution
Westlake Village, California, United States
United States, Colorado
Local Institution
Colorado Springs, Colorado, United States
Local Institution
Denver, Colorado, United States
Local Institution
Loveland, Colorado, United States
Local Institution
Wheat Ridge, Colorado, United States
United States, Florida
Local Institution
Chipley, Florida, United States
Local Institution
Miami, Florida, United States
Local Institution
New Port Richey, Florida, United States
Local Institution
Pinellas Park, Florida, United States
Local Institution
Vero Beach, Florida, United States
Local Institution
Winter Park, Florida, United States
United States, Georgia
Local Institution
Dunwoody, Georgia, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Kansas
Local Institution
Overland Park, Kansas, United States
United States, Kentucky
Local Institution
Lexington, Kentucky, United States
United States, Louisiana
Local Institution
Slidell, Louisiana, United States
United States, Maryland
Local Institution
Chester, Maryland, United States
Local Institution
Silver Springs, Maryland, United States
United States, Massachusetts
Local Institution
Springfield, Massachusetts, United States
United States, Michigan
Local Institution
Berkley, Michigan, United States
Local Institution
Detroit, Michigan, United States
United States, Minnesota
Local Institution
Arden Hills, Minnesota, United States
United States, Mississippi
Local Institution
Gulfport, Mississippi, United States
United States, Missouri
Local Institution
Excelsior Springs, Missouri, United States
Local Institution
Kansas City, Missouri, United States
Local Institution
St. Louis, Missouri, United States
United States, New York
Local Institution
East Syracuse, New York, United States
United States, North Carolina
Local Institution
Charlotte, North Carolina, United States
Local Institution
Greensboro, North Carolina, United States
Local Institution
Hickory, North Carolina, United States
Local Institution
Huntersville, North Carolina, United States
Local Institution
Morehead City, North Carolina, United States
Local Institution
Wilmington, North Carolina, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
United States, Oklahoma
Local Institution
Oklahoma City, Oklahoma, United States
Local Institution
Tulsa, Oklahoma, United States
United States, Oregon
Local Institution
Corvallis, Oregon, United States
Local Institution
Eugene, Oregon, United States
Local Institution
Portland, Oregon, United States
United States, Pennsylvania
Local Institution
Altoona, Pennsylvania, United States
Local Institution
Philadelphia, Pennsylvania, United States
United States, Rhode Island
Local Institution
Cranston, Rhode Island, United States
United States, South Carolina
Local Institution
Anderson, South Carolina, United States
Local Institution
Duncan, South Carolina, United States
Local Institution
Simpsonville, South Carolina, United States
Local Institution
Summerville, South Carolina, United States
United States, Tennessee
Local Institution
Bristol, Tennessee, United States
Local Institution
Kingsport, Tennessee, United States
Local Institution
Knoxville, Tennessee, United States
Local Institution
Memphis, Tennessee, United States
United States, Texas
Local Institution
Dallas, Texas, United States
Local Institution
Houston, Texas, United States
Local Institution
Irving, Texas, United States
Local Institution
Lake Jackson, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
The Colony, Texas, United States
United States, Washington
Local Institution
Olympia, Washington, United States
United States, West Virginia
Local Institution
Bluefield, West Virginia, United States
United States, Wisconsin
Local Institution
Marshfield, Wisconsin, United States
Argentina
Local Institution
Bahia Blanca, Buenas Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Buenos Aires, Argentina
Local Institution
Cordoba, Argentina
Local Institution
Mendoza, Argentina
Australia, New South Wales
Local Institution
Canberra, New South Wales, Australia
Local Institution
Wollongong, New South Wales, Australia
Australia, Queensland
Local Institution
Brisbane, Queensland, Australia
Brazil
Local Institution
Curitiba, Parana, Brazil
Local Institution
Belem, Para, Brazil
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil
Local Institution
Marilia, Sao Paulo, Brazil
Canada, Ontario
Local Institution
Corunna, Ontario, Canada
Local Institution
Hawksbury, Ontario, Canada
Local Institution
Sarnia, Ontario, Canada
Canada, Quebec
Local Institution
Gatineau, Quebec, Canada
Local Institution
Laval, Quebec, Canada
Local Institution
St. Jerome, Quebec, Canada
Canada
Local Institution
St. John's, Canada
France
Local Institution
Rosiers, D'Egletons, France
Local Institution
Labarthe, Sur Leze, France
Local Institution
Husseren, Wesserling, France
Local Institution
Broglie, France
Local Institution
Chartres, France
Local Institution
Gemenos, France
Germany
Local Institution
Viernheim, Schwenningen, Germany
Local Institution
Dresden, Germany
Local Institution
Hamburg, Germany
Local Institution
Nuernberg, Germany
Italy
Local Institution
Ravenna, Italy
Mexico
Local Institution
Tijuana, Baja California, Mexico
Local Institution
Mexico, Distrito Federal, Mexico
Local Institution
Leon, Guanajuato, Mexico
Local Institution
Albuquerque, New Mexico, Mexico
Local Institution
Monterrey, Nuevo Leon, Mexico
Local Institution
Merida, Yucatan, Mexico
Local Institution
Durango, Mexico
Netherlands
Local Institution
Deurne, Netherlands
Local Institution
Ewyk, Netherlands
Local Institution
Hoogvliet, Netherlands
Local Institution
Rijswijk, Netherlands
Local Institution
S Gravenhage, Netherlands
Local Institution
Zwijndrecht, Netherlands
Peru
Local Institution
Arequipa, Peru
Local Institution
Lima, Peru
Puerto Rico
Local Institution
Carolina, Puerto Rico
Local Institution
Guaynabo, Puerto Rico
Local Institution
Ponce, Puerto Rico
Local Institution
Rio Piedras, Puerto Rico
Russian Federation
Local Institution
Moscow, Russian Federation
Local Institution
Saratov, Russian Federation
Local Institution
Smolensk, Russian Federation
Local Institution
St. Petersburg, Russian Federation
Spain
Local Institution
Santiago, de Compostela, Spain
Local Institution
Las Palmas, DE, Spain
Local Institution
A Coruna, Spain
Local Institution
Alicante, Spain
Local Institution
Cadiz, Spain
Local Institution
Granada, Spain
Local Institution
La Coruna, Spain
Local Institution
Madrid, Spain
Local Institution
Oviedo, Spain
Local Institution
Tenerife, Spain
Local Institution
Teruel, Spain
Local Institution
Zaragoza, Spain
United Kingdom
Local Institution
Soham, Cambridgeshire, United Kingdom
Local Institution
Bexhill-on-Sea, East Sussex, United Kingdom
Local Institution
Sunbury on Thames, Greater London, United Kingdom
Local Institution
Aldershot, Hampshire, United Kingdom
Local Institution
Glasgow, Lanarkshire, United Kingdom
Local Institution
Blackpool, Lancashire, United Kingdom
Local Institution
Harrow, Middlesex, United Kingdom
Local Institution
Hastings, Sussex, United Kingdom
Local Institution
Bath, Wiltshire, United Kingdom
Local Institution
Inkberrow, Worcestershire, United Kingdom
Local Institution
Swan Lane, United Kingdom
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00162175     History of Changes
Other Study ID Numbers: CV168-021
Study First Received: September 9, 2005
Last Updated: September 10, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 19, 2013